Browsing Wolfson Institute of Preventive Medicine by Author "Turpie, AGG"
Now showing items 1-7 of 7
-
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.
Turpie, AGG; Farjat, AE; Haas, S; Ageno, W; Weitz, JI; Goldhaber, SZ; Goto, S; Angchaisuksiri, P; Kayani, G; Lopes, RD (Elsevier, 2023-02)BACKGROUND: Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality worldwide. METHODS: GARFIELD-VTE is a prospective, ... -
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials.
Barco, S; Virdone, S; Götschi, A; Ageno, W; Arcelus, JI; Bingisser, R; Colucci, G; Cools, F; Duerschmied, D; Gibbs, H (2023-08-18)BACKGROUND: Antithrombotic treatment may improve the disease course in non-critically ill, symptomatic COVID-19 outpatients. METHODS: We performed an individual patient-level analysis of the OVID and ETHIC randomized ... -
The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE.
Goto, S; Turpie, AGG; Farjat, AE; Weitz, JI; Haas, S; Ageno, W; Goldhaber, SZ; Angchaisuksiri, P; Kayani, G; MacCallum, P (2021-07)INTRODUCTION: Clinical characteristics and outcomes of venous thromboembolism (VTE) patients with concomitant anemia are unclear. This study compares baseline characteristics, treatment patterns, and 24-month outcomes in ... -
Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE
Cohen, O; Ageno, W; Farjat, AE; Turpie, AGG; Weitz, JI; Haas, S; Goto, S; Goldhaber, SZ; Angchaisuksiri, P; Gibbs, H (2022) -
On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease.
Haas, S; Farjat, AE; Pieper, K; Ageno, W; Angchaisuksiri, P; Bounameaux, H; Goldhaber, SZ; Goto, S; Mantovani, L; Prandoni, P (2022-10)Background Direct oral anticoagulants (DOACs) provide a safe, effective alternative to vitamin K antagonists (VKAs) for venous thromboembolism (VTE) treatment, as shown via intention-to-treat comparative effectiveness ... -
Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE.
Jerjes-Sánchez, C; Rodriguez, D; Farjat, AE; Kayani, G; MacCallum, P; Lopes, RD; Turpie, AGG; Weitz, JI; Haas, S; Ageno, W (2021-01)Introduction The risk of venous thromboembolism (VTE) increases during pregnancy and the puerperium such that VTE is a leading cause of maternal mortality. Methods We describe the clinical characteristics, diagnostic ... -
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
Cools, F; Virdone, S; Sawhney, J; Lopes, RD; Jacobson, B; Arcelus, JI; Hobbs, FDR; Gibbs, H; Himmelreich, JCL; MacCallum, P (2022)